NRx Pharmaceuticals, Inc.
NRXP
$3.28
$0.072.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 983.00K | 242.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 983.00K | 242.00K | -- | -- | -- |
| Cost of Revenue | 408.00K | 97.00K | -- | -- | -- |
| Gross Profit | 575.00K | 145.00K | -- | -- | -- |
| SG&A Expenses | 4.57M | 2.81M | 2.74M | 2.94M | 2.60M |
| Depreciation & Amortization | 42.00K | 26.00K | -- | -- | 1.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.58M | 4.36M | 3.73M | 3.75M | 3.63M |
| Operating Income | -4.59M | -4.12M | -3.73M | -3.75M | -3.63M |
| Income Before Tax | 360.00K | -5.89M | -17.58M | -5.51M | -9.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 360.00K | -5.89M | -17.58M | -5.51M | -9.08M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 360.00K | -5.89M | -17.58M | -5.51M | -9.08M |
| EBIT | -4.59M | -4.12M | -3.73M | -3.75M | -3.63M |
| EBITDA | -4.55M | -4.11M | -3.73M | -3.75M | -3.63M |
| EPS Basic | 0.01 | -0.26 | -0.98 | -0.34 | -0.74 |
| Normalized Basic EPS | -0.08 | -0.13 | -0.42 | -0.17 | -0.34 |
| EPS Diluted | 0.01 | -0.26 | -0.98 | -0.34 | -0.74 |
| Normalized Diluted EPS | -0.08 | -0.13 | -0.42 | -0.17 | -0.34 |
| Average Basic Shares Outstanding | 28.96M | 22.23M | 17.93M | 16.41M | 12.25M |
| Average Diluted Shares Outstanding | 28.96M | 22.23M | 17.93M | 16.41M | 12.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |